Palo Alto Networks (NasdaqGS:PANW) Q2 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAdam Borg - Managing DirectorAdam Tindle - Managing DirectorBrad Zelnick - Managing DirectorDipak Golechha - CFOGabriela Borges - Managing Director and Head of US Software Equity ResearchGregg Moskowitz - Managing DirectorHamza Fodderwala - SVP of Investor Relations and Strategic FinanceJohn DiFucci - Senior Managing DirectorJosh Tilton - Managing DirectorLee Klarich - Chief Product and Technology Offi ...

Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $105.3 million, up 12% year-over-year, and $365.3 million for the full year, growing 16% [37] - Adjusted EBITDA for Q4 grew 5% to $39.2 million, and for the full year, it was $113.6 million, growing 14% with an adjusted EBITDA margin of 31% [41] - Cash flow from operations for the year was $91.8 million, up 28% from the prior year [42] Business Line Data and Key Metrics Changes - Core revenues for Q4 grew 15% to $78.2 million, and for the full year, it grew 16% to $317.9 million due to improved client retention and new business production [37] - Policies in force grew 14% to 1.9 million, accelerating from a 13% growth rate in Q3 2025 [41] - Gross payments per franchise increased by 29% year-over-year, indicating stronger cash flow for franchise owners [13] Market Data and Key Metrics Changes - Total written premiums for Q4 were $1.1 billion, growing 13% year-over-year, and for the full year, it was $4.4 billion, up 17% [40] - Contingent commissions for the full year represented 86 basis points of total written premiums, outperforming expectations [39] Company Strategy and Development Direction - The company aims to accelerate growth within existing agencies, expand corporate sales, and scale enterprise and partnership channels while investing in technology [22] - Goosehead is focused on maintaining a long-term mindset and prioritizing quality over quantity in its franchise network [26] - The company is investing heavily in technology, particularly in AI applications, to enhance efficiency and client experience [17][20] Management's Comments on Operating Environment and Future Outlook - Management believes the insurance market is transitioning from a hard market to a healthier environment, which is beneficial for Goosehead [11] - The company expects low double-digit core revenue growth for the first half of 2026, with acceleration anticipated in the second half as pricing dynamics stabilize [38] - Management is confident in the company's position and the potential for long-term growth driven by technology and strategic partnerships [23] Other Important Information - The company has authorized an additional $180 million for share repurchases, reflecting confidence in its valuation [43] - Goosehead has launched a mobile app and an AI-powered virtual assistant, enhancing client interactions and reducing agent involvement [21] Q&A Session Summary Question: How is the company thinking about home closing transactions and the insurance pricing environment for next year? - Management noted that housing construction has not been a significant headwind and that they are not counting on improvements in housing for guidance in 2026 [47] - Pricing guidance ranges from generally down to moderate increases in homeowners pricing [48] Question: How would regulatory changes like profitability caps impact the business model? - Management expressed uncertainty about the likelihood of such changes but noted that nimble markets may be more durable [50] Question: Why does the company believe agents will not be disintermediated through AI? - Management highlighted the complexity of home insurance and the continued demand for human guidance in the process [55] Question: How is the Digital Agent platform expected to impact customer retention? - Management indicated that existing clients purchasing additional policies through the platform could improve retention by rounding out their total account [60] Question: What is the expected investment spending for 2026? - Management expects total cash investment spending to be between $25 million and $35 million, with a portion impacting the P&L [71] Question: How is the health of the agency community and productivity in the franchise channel? - Management reported strong same-store sales growth of 19% in Q4 and noted that the franchise community is healthier than in the past [75]

Glaukos (NYSE:GKOS) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAlex Thurman - CFOAllen Gong - Vice President of Equity ResearchChris Lewis - VP of Investor Relations and Corporate AffairsDavid Roman - Managing DirectorJoanne Wuensch - Managing DirectorJoe Gilliam - President and COORichard Newitter - Managing DirectorThomas Stephan - VP of Medical Technology & SuppliesTom Burns - Chairman and CEOConference Call ParticipantsAdam Maeder - Managing Director and Senior Research Anal ...

Glaukos (NYSE:GKOS) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAlex Thurman - CFOAllen Gong - Vice President of Equity ResearchChris Lewis - VP of Investor Relations and Corporate AffairsDavid Roman - Managing DirectorJoanne Wuensch - Managing DirectorJoe Gilliam - President and COORichard Newitter - Managing DirectorThomas Stephan - VP of Medical Technology & SuppliesTom Burns - Chairman and CEOConference Call ParticipantsAdam Maeder - Managing Director and Senior Research Anal ...

Palo Alto Networks (NasdaqGS:PANW) Q2 2026 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAdam Borg - Managing DirectorAdam Tindle - Managing DirectorBrad Zelnick - Managing DirectorDipak Golechha - CFOGabriela Borges - Managing Director and Head of US Software Equity ResearchGregg Moskowitz - Managing DirectorHamza Fodderwala - SVP of Investor Relations and Strategic FinanceJohn DiFucci - Senior Managing DirectorJosh Tilton - Managing DirectorLee Klarich - Chief Product and Technology Offi ...

Financial Data and Key Metrics Changes - Adjusted EBITDA increased by 10% on a 4% increase in gross transaction value (GTV), reflecting strong execution and cost management [4][11] - Adjusted earnings per share increased by 17% in the fourth quarter and 15% for the full year, driven by higher operating income and lower net interest expense [14] - Full-year adjusted EBITDA is expected to be between $1.47 billion and $1.53 billion, representing approximately 7% growth at the midpoint [15] Business Line Data and Key Metrics Changes - Automotive GTV increased by 3% in the fourth quarter, with unit volumes rising by 2% [11] - Excluding catastrophic impacts, automotive GTV and unit volumes grew approximately 12% and 8% respectively [11] - GTV in the commercial construction and transportation sector increased by 9%, with unit volumes growing approximately 10% [12] Market Data and Key Metrics Changes - Gross returns or salvage values as a percentage of pre-accident cash values expanded, supporting approximately 7% year-over-year growth in the U.S. insurance average selling price [6] - The average price per vehicle sold increased by approximately 1% in the quarter, or roughly 4% excluding catastrophic impacts [12] Company Strategy and Development Direction - The company is focused on disciplined execution and strategic progress, prioritizing scale, longevity, and market share expansion [4][5] - New multi-year agreements with major partners provide long-term visibility into expected volumes and deepen strategic alignment [5][6] - The introduction of the IAA Total Loss Predictor aims to enhance operational efficiencies and strengthen partner economics [8] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding early signs of improvement in seller confidence, supported by stabilizing used equipment values and lower interest rates [9] - The company expects full-year GTV to grow between 5% and 8% in 2026, with a focus on volume-led growth [15] - Management emphasized the importance of continuous improvement in operational efficiency and cost management [46][48] Other Important Information - The company plans to invest between $350 million and $400 million in capital expenditures for 2026, with a focus on technology and traditional physical assets [15][38] - The company is exploring opportunities for share repurchase programs as part of its capital allocation strategy [53] Q&A Session Summary Question: Clarification on 2026 guidance and market share capture - Management confirmed that the guidance includes both annualization of wins and additional terms agreed upon [19][20] Question: Flow-through of GTV to revenue - Management indicated there may be slight pressure on the take rate but remains optimistic about unit economics [21][22] Question: Improvement in the CC&T sector - Management noted early signs of improvement in partner conversations, though the environment remains complex [26] Question: Details on the total loss predictor - Management explained that the tool aims to optimize vehicle routing post-accident, significantly reducing costs [27][30] Question: AI development among customers - Management highlighted varying capabilities among insurance carriers regarding AI investment and integration [34][35] Question: Breakdown of CapEx investments - Management provided a typical mix of 1/3 on technology-related investments and 2/3 on traditional physical assets [38] Question: Total volumes across the auto salvage business - Management stated they do not break down guidance to that level but expect to continue gaining market share [78]

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [9][17][19] - Net income for the full year was $316.9 million, compared to $444.1 million in 2024, while adjusted EBITDA was $657.6 million, up from $632.2 million in 2024 [19][20] - GAAP diluted EPS was $2.50, down from $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared to $4.23 in 2024 [19][20] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10][19] - Phesgo's royalty revenue increased 51% year-over-year to $105.6 million, with total sales growing 48% to approximately $3 billion [11][19] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12][19] Market Data and Key Metrics Changes - ENHANZE-enabled products now include 10 global blockbuster opportunities, with significant approvals in multiple markets including the U.S., Japan, and China [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13][16] Company Strategy and Development Direction - The company aims to expand its ENHANZE portfolio with six new programs entering phase I in 2026, bringing the total development portfolio to 15 products [24][35] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26][27] - The company plans to pursue strategic acquisitions to enhance its drug delivery portfolio while maintaining financial discipline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers and the durability of royalty revenue [23][39] - The company anticipates continued strong growth from existing products and new launches, with a focus on expanding into new therapeutic areas [24][35] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities with long-duration IP [6][27] - The company expects to maintain a strong balance sheet and reduce net debt to below 1x by the end of 2026 [21][22] Q&A Session Summary Question: Regarding the mechanics of DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42][43] Question: On the ADC strategy and regulatory paths - Management indicated that the regulatory pathway for converting IV to subcutaneous delivery would likely follow traditional PK non-inferiority studies [49][50] Question: Update on Hypercon products and clinical testing - Management confirmed that two Hypercon products are on track for phase I clinical testing in 2026, with completion of clinical scale-up batches underway [63][64] Question: Expectations for new partnerships in auto-injectors - Management anticipates progress with high-volume auto-injectors and expects to see interest from both current and new partners [75][76]

Financial Data and Key Metrics Changes - Revenues for Q3 2026 were $16.3 million, an increase from $12.4 million in the previous quarter but a decrease from $40.7 million in the same quarter last year, which included theatrical results from "Terrifier 3" exceeding $20 million [14] - The net loss for the quarter was $875,000, improving by $4.7 million compared to the prior quarter [14] - Adjusted EBITDA for the quarter was $2.4 million, a $6 million improvement from the previous quarter [14] - Direct operating margin improved to 69%, up from 48% in the prior year quarter [8][20] Business Line Data and Key Metrics Changes - The company focused on improving its cost structure and operating margins in its base businesses, achieving a direct operating margin of 69% [8][20] - The acquisitions of Giant Worldwide and IndiCue are expected to significantly enhance revenue and EBITDA, with projected contributions of over $50 million in revenue and $10 million in Adjusted EBITDA for fiscal year 2027 [17][18] Market Data and Key Metrics Changes - The streaming ecosystem saw a monthly unique viewer count of 35.5 million, with SVOD subscribers growing 15% year-over-year to 1.55 million [19] - The content library now exceeds 66,000 total assets, including nearly 58,000 films and episodes, plus over 8,500 podcasts [19] Company Strategy and Development Direction - The company aims to transform into a comprehensive, AI-powered technology services provider for the entertainment industry, leveraging the acquisitions to fill gaps in the market and enhance operational efficiency [6][21] - The focus remains on building a unified, automated architecture for the entire media supply chain, addressing fragmentation in content distribution and monetization [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial guidance for fiscal year 2027, projecting revenues of $115 million to $120 million and Adjusted EBITDA of $10 million to $20 million [12][17] - The acquisitions are seen as a strategic move to capitalize on the industry's shift towards AI integration and automation, with expectations of significant growth in the post- and media services market [24][25] Other Important Information - The company sold 1.725 million shares of common stock at $2 per share, generating net proceeds of $3.2 million for working capital and general corporate purposes [18] - The integration of Giant has been smooth, with a significant increase in business following the acquisition [11][25] Q&A Session Summary Question: Can you discuss the evolution of IndiCue's business and its revenue concentration? - Management noted that IndiCue's revenue concentration has improved year-over-year, with a focus on building durable relationships with a diverse customer base [33][35] Question: Can you provide an update on Matchpoint and its new customers? - Management indicated that new customers are coming through various needs, and the strategy is to expand services once initial contracts are secured [39][41] Question: What are the anticipated synergies from the acquisitions? - Management expects significant revenue and EBITDA synergies from both acquisitions, with potential for $8 million to $9 million in synergies from IndiCue alone [52][54] Question: How will free cash flow be managed moving forward? - Management highlighted that minimal CapEx is required, allowing free cash flow to be reinvested into growth initiatives rather than dilution [64][66] Question: What is the future of acquisitions for the company? - Management stated that while the focus is on integrating the current acquisitions, they remain open to pursuing additional opportunities that align with their strategic goals [81][83]

Beta Bionics (NasdaqGM:BBNX) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsJeffrey Cohen - Managing Director and Director of Equity ResearchJon Block - Managing DirectorMatthew Blackman - Managing DirectorSean Saint - CEOStephen Feider - CFOConference Call ParticipantsDanielle Antalfy - Senior AnalystFrank Takkinen - Senior Research AnalystJeff Johnson - Managing Director and Senior Research AnalystMatthew O'Brien - Managing Director and Seni ...